Advicenne

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management.

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for inflammation and cardio-metabolic diseases. Their product candidates include Naproxcinod for osteoarthritis and NCX 6560 for cardiovascular diseases. They also have products in clinical trials for glaucoma, respiratory disorders, allergic rhinitis, and hypertension. NicOx is working on developing treatments for skin disorders and diabetic retinopathy, among other conditions. The company has partnerships with various organizations for research and development. Founded in 1996, NicOx is based in Sophia Antipolis, France.

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline Vallot to use single-cell technologies to discover innovative treatments for challenging medical conditions.

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small molecule treatments for patients with serious medical needs in fibrosis, lysosomal storage disorders, and oncology. They have developed a pipeline supported by a discovery engine containing a large collection of unique molecules, a research and development facility that they own entirely, and a team with extensive experience in developing compounds targeting nuclear receptors, transcription factors, and epigenetic modulation. By utilizing these assets and expertise, they are progressing two clinical candidates across three indications, in addition to a number of early-stage programs in their pipeline.

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry. The dependence receptors are trans-membrane proteins that receive signals and transmit them inside cells and this helps in controlling tumor development. The company provides vitro and in vivo research, preclinical practices for manufacturing drugs for the treatment of breast cancer, lung cancer, glioblastoma and neuroblastoma cancer.

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient outcomes by utilizing nanophysics in cellular treatment. The company's core philosophy centers around creating innovative physical-based approaches to address the pressing medical needs and challenges faced by many. With its cutting-edge technology, NBTXR3, Nanobiotix aims to significantly enhance the benefits of radiotherapy for cancer patients. Additionally, their Immuno-Oncology program holds great potential in advancing cancer immunotherapies. Nanobiotix is publicly traded on Euronext and the Nasdaq Global Select Market and is headquartered in Paris, France, with additional offices in the United States, Spain, and Germany. For more information, visit www.nanobiotix.com.

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They offer an innovative echotherapy solution that combines HIFU therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumors and varicose veins. Their companyTheraclion a French company created in 2004, a pioneer in the use of ultrasound for therapeutic purposes. Theraclion develops, manufactures, and markets medical devices, the Echopulse®, for non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules. And the SONOVEIN® for the treatment of varicose veins of the lower limbs.

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.

AB Science was established in 2001 by a group of individuals in the medical and business fields who are committed to finding important mechanisms in life science and creating innovative drugs that can greatly improve the lives of patients with significant medical needs. These individuals are pioneers and leaders in the life science industry.

Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to create next-generation immuno-oncology medicines. Kahimmune uses revolutionary insights into the "dark genome" to identify novel neoantigens, resulting in innovative cancer vaccinations developed for synergistic combination therapy.

CTIBiotech is a biotechnology firm that focuses on cancer research, stem cells, governmental consulting, and reviewing medical journals.